Vertebroplasty Does Not Up Pain Relief in Osteoporotic Fracture

Share this content:
Vertebroplasty Does Not Up Pain Relief in Osteoporotic Fracture
Vertebroplasty Does Not Up Pain Relief in Osteoporotic Fracture

THURSDAY, May 10, 2018 (HealthDay News) -- For patients with acute osteoporotic vertebral compression fractures, percutaneous vertebroplasty does not result in significantly greater pain relief than a sham procedure at 12 months, according to a study published online May 9 in The BMJ.

Cristina E. Firanescu, from the Elisabeth TweeSteden Hospital in Tilburg, Netherlands, and colleagues conducted a randomized trial in four community hospitals in the Netherlands from 2011 to 2015 involving 180 participants requiring treatment for acute osteoporotic vertebral compression fractures. Patients were randomized to vertebroplasty or a sham procedure. At each pedicle, participants received subcutaneous lidocaine and bupivacaine; the vertebroplasty group also received cementation.

The researchers found that at all follow-up points after the procedure, the mean reduction in visual analogue scale (VAS) score was statistically significant in the vertebroplasty and sham procedure groups compared with baseline. During 12 months of follow-up, there was no significant difference between the groups in the changes in VAS scores. For secondary outcomes, the results were not statistically significant. In both groups, at all time points the use of analgesics decreased significantly, with no significant difference between the groups.

"Percutaneous vertebroplasty did not result in statistically significantly greater pain relief than a sham procedure during 12 months' follow-up among patients with acute osteoporotic vertebral compression fractures," the authors write.

One author disclosed financial ties to the medical device and medical technology industries.

Abstract/Full Text
Editorial

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths